1. Поддубная И.В. Идарубицин в терапии неходжкинских лимфом. Рос. онкол. журн. 1998; 6: 54–7.
2. Сотников В.М. Лучевая терапия в современных программах лечения неходжкинских лимфом. Автореф. дис. ... д-ра мед. наук. М., 1996.
3. Поддубная И.В. Неходжкинские лимфомы. В кн.: Клиническая онкогематология. Под ред. М.А.Волковой. М.: Медицина, 2001; с. 348.
4. Сouderc B, Dujlos JP, Mokhtari F et al. The managment of adult aggressive non-Hodgkin’s lymphomas. Crit Rev Oncol Hematol 2000; 35 (1): 33–48.
5. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999; 17: 1244–53.
6. Horsman JM, Thomas J, Hough R et al. Primary bone lymphoma: a retrospective analysis. Int J Oncol 2006; 28 (6): 1571–5.
7. Lee CK. Evolving role of radiation therapy for hematologic malignancies. Hematol Oncol Clin North Am 2006; 20 (2): 471–503.
8. Ronson B, Rossi C, Johnson S et al. Locoregional Proton Radiotherapy of a Primary Cavernous Sinus Non-Hodgkin’s Lymphoma: Case Report. Technol Cancer Res Treat 2006; 5 (3): 281–4.
9. Zinzani PL, Martelli M, Magagnoli M et al. How do patients with aggressive non-Hodgkin’s lymphoma treated with third generation regimens (MACOP-B, F-MACHOP) fare in the long-term? Haematologica 1999; 84 (11): 996–1001.